{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"description":"Complete response or partial response based on serum M-Protein assessments. Complete response is defined as absence of original M-protein in serum by immunofixation, and partial response is defined as ≥ 50% reduction from baseline in serum M-protein, both maintained for a minimum of 6 weeks.","groups":[{"description":"Open-label denosumab 120 mg by subcutaneous injection on day 1 of each 28-day cycle with additional loading doses on days 8 and 15 of cycle 1 in participants with plateau-phase multiple myeloma","id":"OG000","title":"Denosumab 120 mg Q4W - Plateau-Phase"},{"description":"Open-label denosumab 120 mg by subcutaneous injection on day 1 of each 28-day cycle with additional loading doses on days 8 and 15 of cycle 1 in participants with relapsed multiple myeloma","id":"OG001","title":"Denosumab 120 mg Q4W - Relapsed"}],"paramType":"NUMBER","populationDescription":"All participants who completed the first cycle of treatment with denosumab","reportingStatus":"POSTED","timeFrame":"Up to 18 months","title":"Complete Response or Partial Response Based on M-Protein Assessments Only","type":"PRIMARY","unitOfMeasure":"Participants"}